Dare Bioscience Q3 EPS Lifted by Brookline Capital Markets

Dare Bioscience, Inc. (NASDAQ:DARE) – Investment analysts at Brookline Capital Markets lifted their Q3 2026 earnings per share (EPS) estimates for Dare Bioscience in a research report issued on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now anticipates that the biotechnology company will post earnings per share of ($0.27) for the quarter, up from their prior forecast of ($0.37). The consensus estimate for Dare Bioscience’s current full-year earnings is ($0.92) per share. Brookline Capital Markets also issued estimates for Dare Bioscience’s Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.92) EPS.

Several other equities analysts also recently issued reports on the stock. HC Wainwright reissued a “buy” rating on shares of Dare Bioscience in a research note on Monday. Wall Street Zen upgraded Dare Bioscience to a “hold” rating in a report on Saturday, May 23rd. Benchmark reissued a “buy” rating on shares of Dare Bioscience in a research note on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Dare Bioscience Price Performance

Dare Bioscience stock opened at $0.82 on Thursday. The stock has a market capitalization of $12.61 million, a P/E ratio of -1.18 and a beta of 1.08. Dare Bioscience has a 12-month low of $0.75 and a 12-month high of $3.78. The firm’s 50-day moving average is $1.68 and its two-hundred day moving average is $1.85.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.00 million. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%.

Institutional Investors Weigh In On Dare Bioscience

Hedge funds have recently modified their holdings of the stock. LPL Financial LLC purchased a new stake in Dare Bioscience in the fourth quarter valued at approximately $28,000. Raymond James Financial Inc. raised its stake in Dare Bioscience by 810.6% during the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 13,650 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Dare Bioscience in the 3rd quarter valued at $37,000. 6.70% of the stock is owned by institutional investors and hedge funds.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.